Ms. Wan Tung is the Manager in charge of pharmaceutical market expansion and LC/Spectro products at Shimadzu Asia Pacific Pte Ltd. She specializes in providing technical consultation to researchers and laboratory professionals, helping them optimize methodologies to achieve accurate and reliable results. With over 15 years of experience in analytical science, Wan Tung is recognized as an expert in LC/SFC/MS technologies. Her expertise spans a broad spectrum of areas, including QAQC regulatory compliance, impurity analysis, drug discovery, and biopharmaceutical applications.

Before joining Shimadzu, she began her career as a QA/QC chemist at a multinational pharmaceutical company. She holds a Bachelor's Honours degree in Chemistry from the University Tunku Abdul Rahman (UTAR).

Mr. Vinit Saxena is the founder and CEO of Sepragen Corporation, which specializes in innovative bio-processing equipment and consumables for producing and purifying biological drugs, nutritional ingredients, and vaccines. Sepragen's patented technologies are utilized globally, contributing to the production of over 40 FDA-approved drugs, including hundreds of millions of doses of two prominent COVID-19 vaccines. The company serves leading biopharma clients across four continents, including Abbvie, Amgen, Novartis, Sanofi, Takeda, Serum Institute and Biocon as well as major nutritional companies like Arla and Mead Johnson.

With over 35 years of industry experience in marketing and manufacturing, Mr. Saxena holds degrees from IIT Kanpur, Syracuse University, and U.C. Berkeley. He has authored over 15 patents and numerous publications, and has been a prominent speaker at industry conferences. Additionally, he serves on the Scientific Advisory Board of The Keck Graduate Institute and has received several SBIR grants and the prestigious IR 100 award.